

**EXECUTIVE SUMMARY [NON-CONFIDENTIAL, NON-TECHNICAL ABSTRACT FOR PUBLIC INFORMATION OR PROGRAM PROMOTION]:** State the application's broad, long-term objectives and specific aims, making reference to the potential public benefits of the project relevant to California. Do not include proprietary or confidential information. This may be distributed before the funding decision has been finalized.

The World Health Organization estimates that by the year 2025, up to 300,000,000 people will suffer from Type 2 diabetes and the accompanying obesity. Elevated levels of blood glucose, fats (triglycerides) and LDL/HDL ratios characterize this syndrome. Drugs are available to treat the elevated blood glucose (thiazolidinediones) and elevated triglycerides and LDL/HDL ratio (fibrates). These drugs function by activating cell proteins termed PPAR receptors. Fibrates (Clofibrate) activate one type of PPAR (PPAR $\alpha$ ) and thiazolidinediones (Avandia, Actos) the other (PPAR $\gamma$ ). My laboratory is proposing a joint venture with Bethesda Pharmaceuticals to develop a single drug that will activate both receptors thus increasing patient compliance and therapeutic efficacy.